Severe respiratory stress causes dyspnea, and a sudden release of this stress frequently accompanies a euphoric sensation. We hypothesized that acute severe respiratory stress may result in an elaboration of endogenous opioids within the central nervous system, and that these opioids may play significant roles in relieving dyspnea and generating euphoric sensation after a sudden removal of the stress. To test this hypothesis, we examined the effects of naloxone (0.04 mg/kg, I.V.) and the placebo (normal saline) on changes in respiratory sensation before and after the release of severe respiratory stress in a double-blind, randomized, crossover study in 14
Although the mechanism of dyspnea has not been fully clarified, an administration of opioids is known to be effective in the management of dyspnea associated with COPD and cancer [1] [2] [3] . Thus it is obvious that exogenous opioids modulate dyspneic intensity. In contrast, the role of endogenous opioids in the modulation of dyspneic sensation is controversial and less clear, although it has been shown in animal studies that respiratory stress produced by inspiratory flow-resistive loads can increase the CSF levels of β-endorphin [4] . The study of Kirsh et al. [5] showed that naloxone, an opiate antagonist, increases neither dyspneic sensation nor ventilatory chemosensitivity during exercise in COPD patients, suggesting that endogenous opioids do not play a significant role in dampening exercise-induced dyspnea in these patients. By contrast, Akiyama et al. [6] showed that naloxone increases respiratory output and dyspnea sensation during acute respiratory stress in healthy adults, suggesting that endogenous opioids modulate the intensity of dyspnea.
It is our commonplace experience in dyspnea studies using healthy human subjects that a sudden removal of healthy adults. Acute severe respiratory stress was induced by loaded breathing with a combination of resistive loading and hypercapnia. The subjects rated their changes in sensation by using a bidirectional visual analogue scale. Naloxone pretreatment affected neither the ventilation nor the development of dyspneic sensation during loaded breathing. Naloxone pretreatment only slightly attentuated the euphoric sensation developed after the release of severe respiratory stress. These findings suggest a small role of opioids in relieving dyspnea and in generating euphoria before and after a sudden removal of stress. [The Japanese Journal of Physiology 55: [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] 2005] Key words: dyspnea, euphoria, naloxone, endogenous opioids. respiratory stress not only causes an immediate relief of dyspneic sensation, but also frequently provides a great degree of euphoric sensation for the subjects of the experiment. Considering the nature of this euphoric sensation, we find it possible that severe respiratory stress may cause an increase in the level of endogenous opioids within the central nervous system, which in turn will contribute to the immediate relief of dyspneic sensation and the generation of euphoric sensation developed immediately after the sudden removal of severe respiratory stress. To test this possibility, we examined the effects of naloxone on changes in respiratory sensation before and after severe respiratory stress induced by a combination of resistive loading and hypercapnia in healthy human volunteers.
METHODS
The studies were performed on 14 healthy male subjects whose ages ranged from 23-42 years. Their average heights and weights were 174.5 ± 5.2 cm and 72.1 ± 10.8 kg (mean ± SD), respectively. The research was carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. The study protocol was approved by the Institutional Ethical Committee of Chiba University, which conforms to the standard set by the Declaration of Helsinki. Each subject gave informed consent to the methodology of the study. None was a smoker, and all were unaware of the hypothesis tested in the studies.
Each subject breathed through an experimental apparatus containing a face mask and a pneumotachograph. Details of the experimental setup are given elsewhere [7] . In brief, ventilatory airflow was measured with the pneumotachograph (CP-100; Allied Health Care Product Inc., St. Louis, MO), and tidal volume (V T ) was obtained by electrical integration of the inspired flow signal.
Mask pressure (P mask ) was measured with a pressure transducer (Transpac IV; Abbott Critical Care Systems, Chicago, IL). End-tidal carbon dioxide tension (P ET CO 2 ) was measured with an infrared CO 2 analyzer (NEC-Sanei-1H21A) through a port in the face mask. Changes in pulse oximeter oxygen saturation (SPo 2 ) were also continuously monitored by a pulse oximeter (Nellcor N-395, Nellcor-Puritan-Bennett Inc., Pleasanton, CA, USA). Inspiratory time (T I ) was defined as the time between the onset and the termination of inspiratory flow, and mean inspiratory flow rate (V T /T I ) was determined.
Dyspneic sensation was induced by a combination of resistive loading and hypercapnia induced by extra dead space (loaded breathing): A plastic tube resistor (3.0 mm in diameter and 70 mm in length) and a plastic tube (30 mm in diameter, 650 mm long, and 460 ml in capacity) were connected in series to the distal limb of the pneumotachograph. The experimental apparatus had a resistance of 58 cm H 2 O/l/s at a flow of 0.5 l/s, and the total instrumental dead space was 0.6 l when the resistive loading and the external dead space were added. Each subject was asked to rate continuously at each breath the intensity of sensation of dyspnea, which was defined as an unpleasant urge to breathe, by using a bidirectional visual analogue scale (VAS). The subject was also informed that there could be a respiratory sensation that we call respiratory euphoria, i.e., a feeling of being "high" or a sensation of being more pleasant than the sensation felt during quiet free breathing.
The analogue scale consisted of a horizontal 20 cm line on the middle of which was a marker of zero. The right end of this line was marked as +100, whereas the left end was marked as -100. The subjects could control the position of the knob of the linear potentiometer along this line. The numerical value of zero indicated "no sensation at all," +100 indicated a sensation that was "intolerably breathless," and -100 indicated "most euphoric (pleasant) imaginable." During the experiments, airflow, V T , P mask , P ET CO 2 , SPo 2 , and the VAS score were all recorded on a thermal array recorder (Omniace RT 3424; NEC, Tokyo, Japan) and stored on a magneto-optical disk for later analysis of the data with a computer program (Omni Win RT34-704; NEC).
The study was conducted on two consecutive days in a double-blind, randomized, crossover design.
The experimental protocol. At the same time on each of the two days, each subject was seated in a comfortable chair and breathed through a tightly fitting face mask connected to the experimental apparatus. Each subject was given a short training period to accustom him to the apparatus, to changes in the sensation of breathing against an added load, and to the use of the VAS (respiratory sensation VAS). Instructions were given that the sensation felt during free breathing before loaded breathing was equivalent to "0." The subjects were also instructed that they could score the negative values of VAS only when they felt what was apparently respiratory euphoria, but not when they simply felt better with the removal of respiratory stress.
When all the respiratory variables were stable, a 2-min recording of the baseline breathing was conducted. Following the baseline respiratory measurements, an intravenous bolus administration of naloxone (0.2 mg/ml solution, 0.04 mg/kg) or placebo (an equivalent volume of normal saline) was done in random order. Randomization was performed by means of sealed envelopes. After the baseline recording was completed, the subject breathed though the experimental apparatus for 2 min without the load in place. The additional respiratory load was then applied and maintained continuously for another 5 min while the subject rated the VAS score at the same time. During the loaded breathing, the distal limb of the experimental apparatus was connected to a T-piece system supplied with 100% oxygen; therefore the loaded breathing test was performed under hyperoxic condition. After the release of loaded breathing, the rating of respiratory sensation was continued until the sensation returned to the preloaded breathing level.
Besides the aforementioned protocols, in 3 of 14 subjects additional experiments were performed to see whether the occurrence of respiratory euphoria upon the relief of dyspnea is a real phenomenon, and also to see whether the duration of loading would affect the VAS score responses. The subjects in these studies had a 5-min loaded-breathing trial before the administration of placebo or naloxone. In the trial, the subjects did not rate dyspneic sensation during the 5-min loaded breathing, but concentrated on rating only the sensation generated after the release of loaded breathing. Then, in accordance with the double-blind, randomized, cross-over design, the subjects received either naloxone or placebo and had a 2-min resting period of breathing that was followed by a 10-min period of loaded breathing. After each experiment the subjects were asked to describe the sensations experienced during respiratory loading and after its release.
Data analysis. A sample size calculation was based on a two-period, two-treatment crossover design. Based on the results of the preliminary study during a 5-min loaded breathing period, the mean values of a respiratory sensation VAS score at 5 min after the start of loaded breathing were 44.8 ± 12.0 (mean ± SD). A minimum clinical difference of a respiratory sensation VAS score of 10 between placebo and naloxone was considered necessary. Thus for a two-sided, 0.05 level of significance test with at least 80% power, a sample of 14 subjects would be adequately powered to detect a statistically significant result.
We analyzed the data obtained during the baseline period, after placebo administration, and after naloxone administration. A breath-by-breath analysis of the records was made. The values of respiratory variables during loaded breathing were obtained every 1 min after the start of loaded breathing from the measurements of at least three consecutive breaths. During the recovery period after the release of respiratory loading, the values of respiratory variables were averaged for each 10 s of the first 1 min and every 30 s thereafter. Furthermore, a VAS score was measured every 5 s for the first 30 s, every 10 s for the next 30 s, and every 30 s thereafter. To analyze changes in respiratory sensation after the removal of respiratory stress, we also calculated the area under the curve (AUC respiratory sensation ) by the trapezoidal method over the entire course of the recovery period while we defined the baseline with a value of zero (respiratory sensation VAS = 0) for each subject. The values of AUC respiratory sensation between naloxone and placebo pretreatment were compared.
The data were expressed as median [interquartile range]. statistical analysis was performed by the use of Friedman's repeated measures of ANOVA, followed by Tukey's test and a signed rank test where appropriate. P < 0.05 was considered significant.
RESULTS
Thirteen of 14 subjects tolerated the 5-min respiratory loading and completed all the study protocols. However, one subject could not tolerate the loading both after the placebo and the naloxone administrations, and the data for respiratory variables and the VAS score at 4 min and 5 min after the start of respiratory loading were not obtainable. In this subject, although the respiratory loading was removed when the respiratory sensation VAS value reached 100, the data for respiratory variables and the VAS score during the recovery period were obtainable.
The 3 subjects in the additional studies tolerated the 10-min respiratory loading and completed all the study protocols. Table 1 lists the values of V T , respiratory frequency (f), minute ventilation (  V I ), mean inspiratory flow rate (V T /T I ), and P ET CO 2 obtained before and after the administration of naloxone and placebo. There was no statistically significant difference in the values of V T , f,  V I , V T /T I , and P ET CO 2 among these 4 different conditions.
Effects of naloxone and placebo on resting ventilation

During loaded breathing
There were large individual variations of the breathing pattern and VAS score during loaded breathing. In most subjects, an addition of respiratory loading caused a gradual increase in V T and a decrease in f with a slow rise in VAS score, whereas in a few subjects, the addition of respiratory loading caused rapid breathing with a rapid rise in VAS score. Table 2 shows changes in ventilatory variables and the VAS score during loaded breathing after placebo and naloxone administration. There was no significant difference between the values of any respiratory variables obtained at any corresponding time during loaded breathing after placebo and naloxone administration. Similarly, no significant difference in the values of VAS score was observed between the placebo and naloxone at any corresponding time.
After removal of loaded breathing Figure 1 shows an example of changes in ventilatory variables and VAS score observed after the removal of loaded breathing in a subject who had received placebo pretreatment. Ventilatory activity progressively decreased in time in an exponential manner. In contrast to a relatively slow change in ventilatory activity, the VAS score decreased rapidly, and there was a small overshoot after which the VAS score gradually returned to zero.
Similar changes in ventilation and VAS score were observed in all subjects, whether they had received either naloxone or placebo pretreatment. Table 3 shows changes in ventilatory variables after the removal of respiratory loading. The removal caused a sudden increase in ventilatory activity, which was followed by an exponential and progressive decrease, requiring about 2 min to return to the resting level of ventilation. There was no significant difference in the values of any respiratory variables between placebo and naloxone administration at any corresponding time after the removal of respiratory loading. The changes in VAS score obtained from all subjects following removal were summarized in Fig.  2 . Thus there was a rapid decrease in the VAS score immediately after the removal, and this decrease was followed by a small overshoot, after which the VAS score gradually returned to zero. At 20-30 s after the removal of respiratory loading, the values of the VAS score after naloxone administration were significantly different from those after placebo administration, suggesting that there was an attenuation of a euphoric sensation after naloxone. The values of AUC respiratory sensation after naloxone administration were also significantly greater than those after placebo administration (naloxone pretreatment: -332. 
T im e a f t e r r e le a s e o f r e s p ir a t o r y lo a d in g
Additional studies
In all 3 subjects of the additional studies, the VAS score consistently showed values of below zero immediately after the 5-min respiratory loading, which gradually returned to zero within 2 min. The responses to respiratory unloading in repeated trials performed on two consecutive days were almost identical, suggesting that the reproducibility of the VAS rating is high (Fig.  3) .
By 10-min respiratory loading after a pretreatment of both placebo and naloxone, there were gradual changes in V T , f, and VAS score, requiring about 3 min to reach near steady levels. Thereafter the breathing pattern and VAS score had been nearly stable for 7 min. Immediately after the release of respiratory loading, the VAS score decreased rapidly with a small overshoot while there was an exponential and progressive decrease in ventilatory activity. These responses of VAS score and ventilatory activity were consistently observed whether the subjects had received either naloxone or placebo and were essentially similar to those observed after the 5-min respiratory loading (Fig. 4) . All subjects stated that they felt a sensation that was more than just a relief of dyspneic sensation immediately after the release of respiratory stress. They also stated that by using the bidirectional VAS, they were able to accurately rate the levels of two qualitatively different respiratory sensations, i.e., dyspnea and respiratory euphoria.
DISCUSSION
The major findings in the present study are as follows: (i) naloxone administration did not affect the resting ventilation; (ii) naloxone pretreatment influenced neither the ventilation nor the development of dyspneic sensation during the loaded breathing; (iii) a sudden removal of severe respiratory stress produced by loaded breathing caused not only an immediate improvement of dyspneic sensation, but also a euphoric sensation in most subjects; (iv) naloxone pretreatment attenuated the euphoric sensation only briefly and to a relatively minor extent.
Our results suggest that endogenous opioids may not modulate the sensation of dyspnea during acute severe respiratory stress. Our results agree with the results of Kirsh et al. [5] who reported that there was no significant difference after naloxone administration compared with after placebo administration in the level of exertional dyspnea and exercise capacity in patients with COPD. However, a simple comparison of our results and theirs may not be entirely valid, since there are many differences in methodology and study population between the two studies.
Our results are in conflict with the observation of Akiyama et al. [6] who showed that naloxone administration increases respiratory output and dyspnea sensation during acute respiratory stress in healthy adults. They explained that the endogenous opioid system suppresses respiratory output under a strong, acute respiratory stress and that this system may relieve the dyspnea sensation secondary to a suppression of the brain stem respiratory center without a specific effect on the central processing for the perception of dyspnea. The discrepancy between their study and ours may be due to the different methods of inducing dyspnea. For example, they employed hypoxic progressive hypercapnia with inspiratory flow-resistive loading as respiratory stimuli to induce the sensation of dyspnea, whereas in our study the dyspneic sensation was induced by a combination of flow-resistive load and hyperoxic hypercapnia. Although conflicting results about the direct effect of hypoxia on the elaboration of endogenous opioids have been reported [8, 9] , it is possible that the absence of hypoxic ventilatory stimulation during respiratory loading in our study might have resulted in an insufficient activation of the endogenous opioid system. Moreover, the duration of the experimental run in our study is shorter than in their study, in which measurements were made after about 10 min of respiratory loading. It is possible that the short duration of respiratory loading in our study might not be a respiratory stimulus strong enough to induce full activation of the endogenous opioids system in the brainstem. Unlike this possibility, however, the results of our additional studies showed that the responses of the VAS score and the ventilatory activity observed during and after a 10-min respiratory loading were essentially similar to those observed during and after a 5-min respiratory loading, suggesting that a longer time of respiratory loading does not affect the responses of the VAS score and ventilatory activity during and after respiratory stress.
Another possibility is that the dose of naloxone used in this study might not be sufficient to reverse the effects of the released endogenous opioids. Although the dose of naloxone used in our study was slightly smaller than that used in the study by Akiyama et al. [6] , this possibility is unlikely since the dose of naloxone used in this study (0.04 mg/kg) was five to ten times the clinical dose and was considered large enough to antagonize the effect of the endogenous opioids [10] . Therefore the finding that naloxone pretreatment never showed an effect during loaded breathing suggests that an elaboration of endogenous opioids in the brainstem during hyperoxic loaded breathing might be minimal and that the effects of endogenous opioids might be masked by the overpowering respiratory stress. The typical change in respiratory sensation after the removal of severe respiratory stress was characterized by a rapid improvement of dyspneic sensation within one or two breaths after the release of stress, followed by a prolonged euphoric sensation lasting for about 1 min. One may argue that the subjects were not euphoric, but only feeling better because of the removal of the severe respiratory stress. However, considering the subjects' comments that they felt a comfortable sensation that is more than merely a relief of dyspnea and that they were able to accurately rate the levels of respiratory sensation, including dyspnea and respiratory euphoria, we consider the overshoot of VAS score beyond zero to represent a real euphoric response.
The mechanism responsible for producing this euphoric sensation is unknown. In contrast to our initial hypothesis that the euphoric sensation might be produced mainly by an elaboration of endogenous opioids, the euphoric sensation was affected by naloxone pretreatment only briefly and to a relatively minor extent. Thus it is unlikely that the endogenous opioid system plays a major role in the generation of the euphoric sensation obtained after the sudden release of severe respiratory stress. Instead, it is more likely that some substances or neurotransmitters other than endogenous opioids in the central nervous system may play a major role in the generation of the euphoric sensation. In this regard, the activation of mesolimbic dopamine is known to produce euphoria [11] . It is possible that a sudden release of severe respiratory stress may cause activation of the dopaminergic systems in the mesolimbic areas, leading to the production of euphoria.
Although the effect seemed to be very small, naloxone pretreatment showed its effect only after the sudden release of severe respiratory stress, indicating that the endogenous opioids system is operative during this period. The result that the values of AUC respiratory sensation after naloxone administration were greater than those after placebo administration also supports this notion. Since the release of severe respiratory stress always accompanied hyperpnea, it is possible that there may be an interaction between lung vagal afferents and naloxone. In this context, Delpierre et al. [12] observed that opioid receptor disinhibition by naloxone can be abolished after either a vagotomy or a cold blockade of large vagal fibers, whereas it persists after a differential blockade of thin vagal fibers, suggesting that pulmonary stretch receptors play an important role in opioid receptor disinhibition. It is well known that hypercapnia has an inhibitory influence on pulmonary stretch receptors [13, 14] . Since a sudden release of respiratory stress causes an immediate improvement of hypercapnia with an increase in tidal volume, a large increase in the activity of pulmonary stretch receptors can be expected, and this increase may contribute to the small attenuation of respiratory euphoria produced by naloxone. Also, this attenuation of euphoric sensation did not accompany the increased ventilation. Thus the opioid-induced euphoric sensation may not be associated with the suppression of respiratory output.
One big problem associated with the design of this study is the use of a bidirectional VAS scale for dyspnea and respiratory euphoria. Like dyspnea, the sensation of respiratory euphoria is not a single sensation; instead it may encompass multiple qualitatively distinct sensations. Although dyspnea and respiratory euphoria are opposite sensations in nature, they are both closely associated with respiration, and it is possible for the subjects to rate the overall generalized sensation as a net effect when the two sensations coexist. In the presence of severe respiratory stress, dyspneic sensation may overpower and mask euphoric sensation, and it seems impossible for the subjects to discern the presence of euphoric sensation even when it exists. However, its presence might be uncovered by a sudden removal of the respiratory stress. Thus a continuous measurement of two qualitatively different sensations using a bidirectional scale may be valid if the degree of respiratory stress is not too much. The unidirectional VAS as a measure of dyspnea is frequently used in experimental and clinical studies, and its reliability and validity has been reported [15, 16] . In our study, we have shown that the reproducibility of the VAS rating using the bidirectional VAS scale is quite high, suggesting the reliability and validity of this technique in our study.
In summary, naloxone pretreatment affected neither the ventilation nor the dyspneic sensation produced during loaded breathing in healthy adult subjects, suggesting that endogenous opioids may not play an important role in damping the dyspnea in the presence of severe respiratory stress. A sudden removal of severe respiratory stress caused not only the relief of dyspnea, but also the generation of a euphoric sensation. Naloxone pretreatment attenuated the euphoric sensation after the release of severe respiratory stress only briefly and to a relatively minor extent, suggesting that the endogenous opioid system would play only a small role in the generation of the euphoric sensation developed after the sudden release of severe respiratory stress.
